Development & Clinical Application of K-PaC Registry Version 2.0

Development and clinical use of pancreatic cancer registry

* Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029 * Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Pancreatic Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Diseases Pancreatic Neoplasms

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cancer Center

Goyang, Gyeonggido, 10408, South Korea

About this study

We plan to collect retrospective and prospective data based on medical data centered on EMR. ∙ This registry is built on EMR data containing specific information on medical provider records and patient health records. It is designed to enable the confirmation of specific treatment history and medical staff records, and to generate highly valid RWD-based evidence through EMR information such as accurate diagnosis of disease, treatment method, symptom changes, monitoring of lab data values, and patient status. ∙ Based on the built registry data, it is possible to conduct research based on evaluation of drug treatment and additional comparison of indications for elderly or poor general condition patients who are excluded from regular clinical trials, as well as research on diagnosis and prognosis. The clinical information and biomarkers of the prospective patient group are analyzed to evaluate the correlation with treatment response, overall and progression-free survival rates.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of pancreatic cancer

Exclusion criteria

In cases where medical record review is not feasible

Treatment and study plan

Primary outcomes

Development and clinical use of a pancreatic cancer registry

Time frame: From initial diagnosis to death

Development of K-PaC Registry v.2.0: Retrospective data integration from 2010 to 2022 and prospective data collection from more than 811 enrolled patients from 2023 to 2029Creation of clinical evidence (RWE) based on pancreatic cancer real-world data (RWD): 3 or more

Secondary outcomes

Assessing the association between pancreatic cancer biomarker markers and treatment response, overall and progression-free survival

Time frame: From initial diagnosis to death

Transcriptome, Whole genome, Epigenome, Proteome, Metabolome

Sponsors and collaborators

Lead sponsor

National Cancer Center, Korea

Other Gov

Registry information

Important dates

Study start: 2023
Primary completion: 2029
Study completion: 2030
First posted: Sep 12, 2025
Registry last updated: Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation